pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›Upneeq
drug
save

oxymetazoline hydrochloride

Marketedupdated 3mo ago
by RVL Pharmaceuticals Inc
Approved
community read0 votes

🐶 often sniffed alongside

top 3
  • drugoxymetazoline1 co-mentions · 1 sources
  • companyBeijing Chao-Yang Hospital1 co-mentions · 1 sources
  • tagOphthalmology1 co-mentions · 1 sources

all catalysts(1)

phase 2 initiation · 1
Apr 26, 2026
phase 2 initiation
4mo ago
Beijing Chao-Yang Hospital — oxymetazoline hydrochloride (Phase II Trial Initiation)
oxymetazoline hydrochloride
→

Trials studying oxymetazoline hydrochloride

  • phase3LIDRISE Study: A Phase 3 Study on the Efficacy and Safety of STN1013800 (Oxymetazoline HCl 0.1% Eye Drops, Single Dose) in the Treatment of Acquired Blepharoptosis.recruitingn=234

Patent cliff

source: FDA Orange Book
first barrier falls
May 2, 2028
~1.7 years out

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (19)

  • Dec 16, 2039method-of-use (U-2849)US 10799481
  • Dec 16, 2039formulationUS 10814001
  • Dec 16, 2039formulationUS 10898573
  • Dec 16, 2039method-of-use (U-2849)US 10940138
  • Dec 16, 2039formulationUS 11103482
  • Dec 16, 2039formulationUS 11311515
  • Dec 16, 2039method-of-use (U-2849)US 11324722
  • Dec 16, 2039formulationUS 11541036
  • Dec 16, 2039method-of-use (U-2849)US 11701343
  • Jun 11, 2035method-of-use (U-2567)US 10335391
  • Jun 11, 2035method-of-use (U-2921)US 10751325
  • Jun 11, 2035method-of-use (U-3494)US 11517560
  • Jun 11, 2035method-of-use (U-3494)US 12350255
  • Jun 11, 2035method-of-use (U-2306)US 9974773
  • Dec 1, 2031formulationUS 8883838
  • Aug 26, 2031method-of-use (U-2849)US 10912765
  • Aug 26, 2031method-of-use (U-2849)US 8357714
  • Aug 26, 2031method-of-use (U-2849)US 9867808
  • May 2, 2028method-of-use (U-1959)US 78120491.7y

News(0)

no news has mentioned this drug yet

brand
Upneeq
generic
oxymetazoline hydrochloride
indication
Ptosis
phase
marketed
Data sources
ClinicalTrials.gov
last refreshed 8m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?